Disposition of 26454 shares by Joseph Ciaffoni of Collegium Pharmaceutical at 21.34 subject to Rule 16b-3

COLL Stock  USD 29.96  0.45  1.48%   
About 68% of Collegium Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Collegium Pharmaceutical stock suggests that many investors are alarmed at this time. Collegium Pharmaceutical's investing sentiment shows overall attitude of investors towards Collegium Pharmaceutical.
  
Filed transaction by Collegium Pharmaceutical Director, Officer President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 26454 stock option (right to purchase) at 21.34 of Collegium Pharmaceutical by Joseph Ciaffoni on 2nd of June 2024. This event was filed by Collegium Pharmaceutical with SEC on 2023-12-20. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Collegium Pharmaceutical's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Collegium Pharmaceutical's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Collegium Pharmaceutical Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Collegium Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Collegium Pharmaceutical Fundamental Analysis

We analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Revenue

Revenue Comparative Analysis

Collegium Pharmaceutical is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Collegium Pharmaceutical Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Collegium Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics with similar companies.

Peers

Collegium Pharmaceutical Related Equities

SLNOSoleno Therapeutics   5.77   
0%
100.0%
TILInstil Bio   5.61   
0%
97.0%
AKTXAkari Therapeutics   4.84   
0%
83.0%
CAPRCapricor Therapeutics   4.67   
0%
80.0%
BPTHBio Path   2.50   
0%
43.0%
CTMXCytomX Therapeutics   2.30   
0%
39.0%
ASMBAssembly Biosciences   2.17   
0%
37.0%
ACHLAchilles Therapeutics   0.93   
16.0%
0%
CRNXCrinetics Pharmaceuticals   1.70   
29.0%
0%
MBRXMoleculin Biotech   3.53   
61.0%
0%
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out Collegium Pharmaceutical Hype Analysis, Collegium Pharmaceutical Correlation and Collegium Pharmaceutical Performance.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.49)
Earnings Share
2.34
Revenue Per Share
18.538
Quarterly Revenue Growth
0.165
Return On Assets
0.0968
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.